Search

Displaying results 2091 - 2100 of 10000 in total
  1. Indication

    Coccidioidomycosis

    go.drugbank.com/conditions/DBCOND0000138
    Drugs: Amphotericin B · Fluconazole · Ketoconazole · Posaconazole · Voriconazole
    Synonyms: San Joaquin valley fever
  2. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  3. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  4. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … [L40793] Approximately 50% of patients with primary MF have a mutation of the _JAK2_ gene, which is also commonly mutated in patients with polycythemia vera or essential thrombocythemia.

  5. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    MPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites. … Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients.

  6. Drug

    Sasanlimab

    go.drugbank.com/drugs/DB18849
    Investigational

    Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).

  7. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: CORTINOL D, Phenoris OntSynonyms: 5-chloro-7-iodoquinolin-8-ol
  8. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413] … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

    Synonyms: alpha-D-galactosidase, alpha-D-galactopyranosidase
  9. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma … of cytokine release syndrome (CRS), a serious condition associated with the use of immunotherapy.

  10. Drug

    Procaine

    go.drugbank.com/drugs/DB00721
    ApprovedInvestigationalVet approved

    A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. … Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

    Categories: Esters of Aminobenzoic Acid, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use